Beyond weight loss: multisystem benefits of obesity medications - PubMed
an hour ago
- #obesity medications
- #multisystem benefits
- #GLP-1 receptor agonists
- Obesity medications are recognized as disease-modifying therapies for obesity, addressing it as a gateway disease linked to various health conditions.
- The review highlights medications including phentermine-topiramate, naltrexone-bupropion, GLP-1 receptor agonists (e.g., liraglutide, semaglutide), and newer GLP-1-based agents (e.g., tirzepatide).
- Benefits extend to type 2 diabetes, metabolic liver disease, chronic kidney disease, heart failure, cardiovascular disease, sleep apnea, PCOS, osteoarthritis, depression, and more.
- GLP-1-based and multiagonist therapies show beneficial effects across comorbid conditions, often beyond just weight loss.
- Evidence indicates weight loss-independent effects, especially with GLP-1 receptor agonists, important for personalized obesity management.